STOCK TITAN

Olema Pharmaceuticals (NASDAQ: OLMA) inks 7-year HQ lease with $18.5M base rent

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Olema Pharmaceuticals, Inc. entered a seven-year lease with KR Oyster Point II, LLC for a new headquarters totaling approximately 38,176 square feet across two floors in South San Francisco. The company plans to relocate its corporate headquarters to this space by December 2026 as existing San Francisco leases expire between December 2026 and January 2027.

The Lease sets total base rent of $12,361,188.00 for Phase I and $6,145,463.76 for Phase II during the initial term, net of rent abatement. Olema must provide a cash security deposit of $427,546.80 and may terminate once at month 60 by paying a $1,716,240.96 fee. The agreement includes a five-year extension option and a right of first offer on additional space, while the landlord funds specified build-out work and can terminate if Olema fails to cure certain breaches.

Positive

  • None.

Negative

  • None.
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Total leased area 38,176 square feet Combined Phase I and Phase II premises
Phase I area 25,048 square feet Fourth floor space under the lease
Phase II area 13,128 square feet Fifth floor space under the lease
Phase I base rent $12,361,188.00 Total base rent over initial term, net of abatement
Phase II base rent $6,145,463.76 Total base rent over initial term, net of abatement
Termination fee $1,716,240.96 Fee to terminate at end of 60th full month
Security deposit $427,546.80 Cash security deposit required under the lease
Initial lease term 7 years Initial Term of the lease agreement
Material Definitive Agreement regulatory
"Item 1.01 Entry into a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
Initial Term financial
"The initial term of the Lease is seven years (the “Initial Term”)"
rent abatement financial
"total base rent for Phase I during the Initial Term, net of rent abatement"
right of first offer financial
"a right of first offer to expand the size of the Premises"
A right of first offer is a contractual agreement that requires an owner to offer an asset or stake to a designated party before marketing it to others; the holder gets the first chance to negotiate terms directly with the seller. For investors, it matters because it can limit who can buy or set the sale price path—like getting the first invitation to buy a sought-after item before it goes on general sale, protecting potential access or controlling competition.
operating expenses financial
"the Company to pay its pro rata share of operating expenses and certain taxes"
Operating expenses are the routine costs a company pays to keep its business running day to day — things like salaries, rent, utilities, office supplies, and marketing. Investors watch them because they reduce the profit available to shareholders and reveal how efficiently a company runs; lower or well-controlled operating expenses (relative to revenue) are like trimming household bills to improve savings.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
false000175028400017502842026-04-272026-04-27

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 27, 2026

 

 

Olema Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39712

30-0409740

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

780 Brannan Street

 

San Francisco, California

 

94103

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 415 651-3316

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

OLMA

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 1.01 Entry into a Material Definitive Agreement.

On April 27, 2026, Olema Pharmaceuticals, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with KR Oyster Point II, LLC, a Delaware limited liability company (the “Landlord”), pursuant to which the Company will lease an aggregate of approximately 38,176 square feet, consisting of 25,048 square feet of space located on the fourth floor (the “Phase I”) and 13,128 square feet of space located on the fifth floor (“Phase II” and together with Phase I, the “Premises” ). The Company intends to relocate its corporate headquarters to the Premises by December 2026. The Company’s existing leases for its office and lab space in San Francisco are scheduled to expire between December 2026 and January 2027.

Prior to the commencement of the Lease, the Landlord will perform certain items of work on the Premises in accordance with the Lease, including the work agreement attached thereto (collectively, the “Landlord Work”). Except as otherwise expressly set forth in the Lease, the Landlord will be responsible for all costs associated with the Landlord Work.

The initial term of the Lease is seven years (the “Initial Term”), unless earlier terminated in accordance with the Lease. The Company has a one-time option to terminate the Lease at the end of the 60th full calendar month of the Initial Term, with, among other requirements, the payment to Landlord of a termination fee in an amount equal to $1,716,240.96. The Lease also requires a cash security deposit in the amount of $427,546.80. The Lease also provides the Company with an option to extend the term for one additional five-year period and a right of first offer to expand the size of the Premises to Suite 550 located on the fifth floor and the entire sixth floor.

The lease term for Phase I will commence on the earlier of (i) the date the Company first conducts business in Phase I or (ii) the date that the Landlord delivers exclusive possession of Phase I in the condition required under the Lease, which is expected to be on or about September 15, 2026. The Lease provides that total base rent for Phase I during the Initial Term, net of rent abatement, is $12,361,188.00.

The lease term for the Phase II commences on the earlier of (i) the date the Company first conducts business in Phase II or (ii) the date that the Landlord delivers exclusive possession of Phase II in the condition required under the Lease, which is expected to be on or about December 1, 2026. The Lease provides that total base rent for Phase II during the Initial Term, net of rent abatement, is $6,145,463.76.

The Lease contains customary provisions requiring the Company to pay its pro rata share of operating expenses and certain taxes, assessments and fees related to the Premises and provisions allowing the Landlord to terminate the Lease if the Company fails to remedy a breach of certain of its obligations within specified time periods. The Company and Landlord have made customary representations, warranties and covenants in the Lease.

The foregoing description of the Lease does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease, a copy of which will be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 


OLEMA PHARMACEUTICALS, INC.

 

 

 

 

Date:

May 1, 2026

By:

/s/ Sean Bohen, M.D., Ph.D.

 

 

 

Sean Bohen, M.D., Ph.D.
President and Chief Executive Officer

 


FAQ

What lease agreement did Olema Pharmaceuticals (OLMA) enter into?

Olema Pharmaceuticals entered a seven-year lease with KR Oyster Point II, LLC for 38,176 square feet of office and lab space, split between two floors, intended to become its new corporate headquarters as current San Francisco leases approach expiration in late 2026 and early 2027.

How much space is Olema Pharmaceuticals (OLMA) leasing at its new headquarters?

Olema is leasing approximately 38,176 square feet in total, including 25,048 square feet on the fourth floor (Phase I) and 13,128 square feet on the fifth floor (Phase II). This combined area is expected to accommodate the company’s future headquarters and related operations.

What are the base rent commitments in Olema Pharmaceuticals’ new lease?

The lease provides total base rent of $12,361,188.00 for Phase I and $6,145,463.76 for Phase II over the initial seven-year term, net of rent abatement. These amounts reflect Olema’s core rental obligations, excluding its share of operating expenses, taxes, assessments, and related fees.

What options and termination rights does Olema Pharmaceuticals (OLMA) have under the lease?

Olema has a one-time right to terminate the lease after the 60th full month of the initial term by paying a $1,716,240.96 termination fee. The company also holds an option to extend the lease for an additional five-year period, subject to the lease’s conditions.

When will Olema’s new lease phases commence and when is relocation expected?

Phase I is expected to commence around September 15, 2026, and Phase II around December 1, 2026, tied to occupancy or delivery conditions. Olema intends to relocate its corporate headquarters to the new premises by December 2026, aligning with the expiration of current leases.

What additional financial obligations does Olema Pharmaceuticals have under the new lease?

Beyond base rent, Olema must provide a $427,546.80 cash security deposit and pay its pro rata share of operating expenses, taxes, assessments, and related fees. The landlord funds specified build-out work, while Olema remains responsible for ongoing obligations defined in the lease terms.

Filing Exhibits & Attachments

1 document